Maze Therapeutics (NASDAQ:MAZE) Shares Gap Down – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE) gapped down before the market opened on Thursday . The stock had previously closed at $29.58, but opened at $28.40. Maze Therapeutics shares last traded at $28.0550, with a volume of 56,132 shares.

Wall Street Analyst Weigh In

MAZE has been the subject of a number of research reports. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Price Performance

The stock has a market cap of $1.52 billion, a P/E ratio of -10.89 and a beta of 2.21. The company’s 50 day moving average price is $28.74 and its 200-day moving average price is $31.90. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the sale, the chief executive officer owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This represents a 59.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,110 shares of company stock worth $3,057,531 over the last ninety days. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares in the last quarter. TRV GP IV LLC bought a new stake in Maze Therapeutics in the second quarter worth approximately $133,502,907. ARCH Venture Management LLC acquired a new position in Maze Therapeutics in the second quarter valued at approximately $122,983,582. BlackRock Inc. acquired a new position in Maze Therapeutics in the second quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.